Funding for this research was provided by:
Chemie-Wirtschaftsförderungsgesellschaft
Friedrich-Alexander-Universität Erlangen-Nürnberg
Article History
Received: 30 August 2022
Accepted: 24 October 2022
First Online: 5 November 2022
Declarations
:
: E. Leibold is employed by BASF SE, a former manufacturer of UV-327; however, BASF SE was not involved in the study design nor in the evaluation or interpretation of the results. C. Fischer, J. Hiller, and T. Göen have no conflicts of interest to declare.
: The study has been approved by the ethics committee of the medical faculty of Friedrich-Alexander-Universität Erlangen-Nürnberg (49_18 B) and has been performed in accordance with all relevant ethical standards. All study participants gave their written and informed consent to participate in the study.